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The synthesis and biological evaluation as antiviral agents of a series of racemic 4-aryl-1,2,3-
triazolyl carbanucleosides of type (±)-10/(±)-11 related to the broad spectrum antiviral agent 
ribavirin 1 are described. These compounds were produced using a “click chemistry” strategy 
starting from readily available protected alcohol 13b. The synthetic approach made use of olefin-
based organic reactions for the stereoselective construction of the appropriately functionalized 
cyclopentane ring moiety followed by copper (I) catalyzed Huisgen 1,3-dipolar cycloaddition of 
azides and alkynes for the regioselective construction of the heterocyclic triazole moiety.  
 






Ribavirin (Virazole®, 1, Figure 1)1 is a broad spectrum antiviral in clinical use for the treatment 
of RSV infections, lassa fever, hepatitis (A, B, and C), measles and mumps. The structure of this 
nucleoside analogue consists in a β-D-ribose ring attached to a 1,2,4-triazole derivative replacing 
the classic purine or pyrimidine base as the aglycon. Other nucleoside analogues owning 5-
membered heterocyclic bases, such as imidazoles and triazoles, have displayed interesting 
biological properties; for instance, brenedin (Mizoribine®, 2, Figure 1) is currently in clinical use 
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as an immunosuppressor for the treatment of transplant patients2 and EICAR (3, Figure 1), 
causes depletion of purine nucleotides resulting in a broad spectrum of activity against RNA and 
DNA viruses and tumour cell proliferation.3 
In this context, a great number 1,2,3-triazole derivatives have shown a great potential as 
antiviral, antibacterial or antiproliferative agents,4 with 1,2,3-triazolyl nucleoside derivatives 






















4 R = acyl, alkyl. 5 R = halogen
AcO
Rivabirin 1, X = N 
Brenedin 2, X = C    OH
EICAR    3, X = C     C     CH  
 
Figure 1. Selected nucleoside analogues with imidazole or triazole bases owning remarkable 
biological activities.  
 
Furthermore, we and others have recently reported several examples of 1,2,3-triazolyl 
carbanucleosides owning promising biological activities (Figure 2).7 For example, compound 
(±)-6 (R = 2-C6H4OMe) exhibited specific inhibitory potential against TK+VZV (EC50 = 11 
μM),8 7 was found to own moderate activity against HIV-1 (IC50 = 43.8 μM),9 and 810 displayed 





















(±)-6 R = CO2Me, CONH2, Ar (±)-7 8  
 
Figure 2. Recently reported 1,2,3-triazolyl carbanucleosides with antiviral activities.  
 
In recent times we have started a research program devoted to the synthesis and biological 
evaluation as antiviral and antitumoral agents of carbanucleosides produced using, in some 
extent, the postulates of “click chemistry”. In our previous work,8 we reported on a series of 
racemic 4-aryl-1,2,3-triazolyl 2’,3’-dideoxy-2’-iodocarbanucleosides of type (±)-6 (Figure 2) and 
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4-aryl-1,2,3-triazolyl 2’,3’-dideoxy-2’,3’-didehydrocarbanucleosides of type (±)-9 (Figure 3). 
These triazolyl carbanucleosides, structurally related to ribavirin 1, were produced using a 
iodoazidation reaction as the key step for the stereoselective construction of the desired 
functionalized cyclopentane ring, followed by the regioselective assembly of the heterocyclic 
moiety by a Cu(I) catalysed Huisgen 1,3-dipolar cycloaddition.11  
We present here our advances on the topic, reporting the synthesis and biological evaluation 
as antiviral agents of a series of 4-aryl-1,2,3-triazolyl 3’-deoxycarbanucleosides, of type (±)-10 
and (±)-11 (Figure 3). These compounds were designed to explore the effect on the antiviral 
activities of a different pattern of substitution at position 2’ of the carbocycle, as well as the 
modification of the relative stereochemical configuration of the base with regard to the 














(±)-10 (±)-11  
 
Figure 3. Previously 1,2,3-triazolyl carbanucleosides reported by our group (±)-9,8 and target 
compounds (±)-10/(±)-11.  
 
 
Results and Discussion 
 
Even when the number of references related to the “click chemistry” topic is increasing 
exponentially since the seminal review by Kolb, Finn and Sharpless,12 the original postulates are 
(in most of the cases) restricted to the use of the ubiquitous Cu(I) catalysed Huisgen’s 1,3-dipolar 
cycloaddition.11 In a recent review by Moorhouse and Moses,13 intelligently entitled: Click 
Chemistry and Medicinal Chemistry: A Case of “Cyclo-Addiction”, the authors stated: It is 
important to remember that “click chemistry” was originated before the evolution of the Cu(I) 
catalyst modification of the Huisgen cycloaddition, and that there are other examples of 
reactions that meet the “click chemistry” criteria, including mainly olefin based reactions.  
Taking this considerations into account, we felt that our strategy for the rapid synthesis of 
carbanucleoside derivatives could not be only restricted to the use of the Huisgen cycloaddition 
for the construction of the heterocyclic base. For this reason, the designed strategy (Scheme 1) 
for the synthesis of our target compounds was intended to use olefin-based reactions as the key 
steps for the synthesis of the corresponding pseudosugar scaffold.  
ISSN 1551-7012 Page 154 ©ARKAT USA, Inc. 




















Scheme 1. Retrosynthetic analysis for the synthesis of target compounds (±)-10/(±)-11.  
 
As shown in Scheme 1, the synthesis of target compounds (±)-10/(±)-11 could be tackled by 
epoxidation of readily available protected derivatives of cyclopent-3-enylmethanol of general 
structure 13, leading to a mixture of epimers 14 that, upon nucleophilic ring opening of the 
oxirane ring, would lead to a mixture of stereoisomers (±)-15. Construction of the heterocyclic 
base using Cu(I) catalysed Huisgen 1,3-dipolar cycloaddition,11 and further deprotection of the 
corresponding hydroxymethyl group, would lead to the target compounds. This synthetic plan 
would enable us to prepare several racemic 1,2,3-triazolocarbanucleoside derivatives differing in 
the relative stereochemical configuration of the functional groups attached to positions 1’, 2’ and 
4’ in the cyclopentane ring, with derivatives of type (±)-10 having a cis relationship between the 
base and the hydroxymethyl group at position 4’ (the same relative configuration of natural 
nucleosides), and derivatives of type (±)-11, having a trans relationship between the above 
mentioned substituents.  
Starting from readily available known alkenes 13a15 and 13b8 (Scheme 2), epoxidation of 
13a using MCPBA led, after purification by flash column chromatography, to a mixture of 
cis/trans epimers 14a/b in a 1:8 ratio as previously reported,14,15 with an improved yield of 91% 
(69% in the original paper).15 The reaction of 13b with MCPBA produced, after chromatographic 
purification, an 81% yield of a mixture of cis/trans epimers 14c/d in a 1:3.8 ratio (by 1H-
NMR).16 In both cases, attempts of separation of the mixtures were unsuccessful, leading only to 















R = TBDMS: 14a13a (±)-15a (±)-15b






Scheme 2. Epoxidation of alkenes 13 and nucleophilic ring opening with sodium azide of the 
corresponding epoxides of type 14. 
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Concerning the nucleophilic ring opening of the resulting epoxides 14a/b and 14c/d, we 
selected the reaction conditions developed by Crotti et al,17 that produced mixtures of racemic 
monoprotected azidoalcohols (±)-15a/b in a 86% yield and (±)-15c/d in a 94% yield (Scheme 2). 
Resolution of those by flash column chromatography was much easier than for the mixtures of 
epimeric epoxides 14a/b and 14c/d (see experimental section), so the needed separation of the 
corresponding isomers was performed at this stage of the synthetic route.  
Since we wished to evaluate the effect on the biological activities of the relative 
configuration of the base and the hydroxymethyl group on position 4’ of the cyclopentane ring of 
target compounds (±)-10/(±)-11, we consequently decided to follow the synthetic plan using the 
TBDPS diastereomeric precursors ((±)-15c/d), as they could be produced in more equitable 
quantities than their TBDMS ((±)-15a/b) counterparts.  
Construction of the desired 4-aryl-1,2,3-triazole moiety was achieved (Scheme 3 and Table 
1) using Cu(I) catalysed Huisgen’s 1,3-dipolar cycloaddition.11,18 As expected, this methodology 
produced only one of the two possible regioisomers ((±)-16a-c/(±)-17a-c). Using large amounts 
of DIPEA and excess CuI (Method B) the reaction yielded the corresponding 1,2,3-triazole 
derivatives with good yields (entries 2, 5-7; Table 1). On the contrary, differing from our 
previous results,8 only moderate yields of the desired products (±)-16a-c (entries 1, 3, 4; Table 1) 
were obtained using 2 equivalents of the base and a catalytic amount of CuI (Method A). In 
addition, in most of the cases (entries 1-6, Table 1), a small amount of the corresponding triazole 
iodinated at position 5 of the heterocycle was isolated ((±)-18a-c/(±)-19a-b).19 Deprotection of 
the silyl protecting group using TBAF generated the target compounds (±)-10a-c/(±)-11a-c in 












(±)-16a-c (R = TBDPS)

























(±)-17a-c (R = TBDPS)




Scheme 3. Cu(I) catalysed Huisgen’s 1,3-dipolar cycloaddition of azides ((±)15c/d with terminal 
aryl alkynes (see Table 1 for details) and deprotection of the TBDPS protecting group leading to 
target compounds (±)-10a-c/(±)-11a-c.  
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Table 1. Synthesis of 4-aryl-1,2,3-triazoles (±)-16a-c and (±)-17a-c 
Entry Substrate Ar Method a T t (h) Products (% yield) b,c 
1 (±)-15c C6H5 A r.t. 62 (±)-16a (30) + (±)-18a (13) 
2 (±)-15c C6H5 B reflux 136 (±)-16a (72) + (±)-18a (3) 
3 (±)-15c 4-C6H4Me A r.t. 40 (±)-16b (42) + (±)-18b (4) 
4 (±)-15c 4-C6H4OMe A r.t. 40 (±)-16c (23) + (±)-18c (11) 
5 (±)-15d C6H5 B reflux 222 (±)-17a (64 )+ (±)-19a (5) 
6 (±)-15d 4-C6H4Me B reflux 209 (±)-17b (82) + (±)-19b (5) 
7 (±)-15d 4-C6H4OMe B reflux 250 (±)-17c (68) 
aMethod A: DIPEA (2 eq.), CuI (0.05-0.1 eq). Method B: DIPEA (50 eq.), CuI (1-2 eq.). 
bIsolated yields after flash column chromatography. cFor entries 3 and 4, a 42 % of the starting 
material (±)-15c was also recovered. 
 
X-ray analysis of a single crystal of the intermediate (±)-16a unequivocally confirmed its 
relative configuration (Figure 4) and, consequently, that of its precursor, (±)-15c, as well as 
indirectly those of their respective epimers, (±)-17a and (±)-15d, and those of the compounds 





Figure 4. Mercury ellipsoid projection (50% probability) of the molecular structure of 
compound (±)-16a, with a random numbering scheme. Hydrogen atoms, except those involved 
in the relative stereochemical configuration (H1, H3 and H4), are omitted for clarity.20 
 
Target compounds ((±)-10a-c, (±)-11a-c), as well as the monoprotected intermediates (±)-
16a-c, and (±)-18a/c, were evaluated for their inhibitory activities against: parainfluenza virus-3, 
reovirus-1, Sindbis, Coxsackie B4, and Punta Toro virus in Vero cell cultures; herpes simplex 
virus type 1 (strain KOS), herpes simplex virus type 1 (TK− KOS ACV), herpes simplex virus 
type 2 (strain G), vaccinia virus, and vesicular stomatitis virus in human embryonic lung (HEL) 
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cells; and vesicular stomatitis virus, respiratory syncytial virus and coxsakie B4 virus in human 
epithelial (HeLa) cells. These activities were compared with those of acyclovir, gancyclovir, 
brivudin, (S)-DPHA, and ribavirin. Furthermore, the inhibitory activities of (±)-10a-c, (±)-11a-c, 
(±)-16b-c, and (±)-18c against Feline Corona and Feline Herpes viruses in Crandell–Rees feline 
kidney (CRFK) cells were measured, and the obtained activities compared with those of HHA, 
UDC and ganciclovir.  
Compounds (±)-10a-c, (±)-11a-c, (±)-16a-c, and (±)-18a/c were also evaluated for its 
inhibitory activities against Cytomegalovirus (CMV Davis strain) in HEL cell lines, and the 
results contrasted with those of ganciclovir and cidofovir. Likewise, these compounds were also 
evaluated for their inhibitory activities against influenza viruses (Influenza A (H1N1/ H3N2 
subtypes) and Influenza B) in MDCK cell lines, and the results compared with those of 
oseltamivir carboxylate and ribavirin.  
In all the cases, these 1,2,3-triazolocarbanucleosides did not show any specific antiviral 
effects (i.e. minimal antiviral effective concentration ≤ 5-fold lower than the minimal cytotoxic 
concentration for the host cell) against any of the viruses in the assay systems used.  
More promising results were obtained in the antiviral evaluation of the silylated derivatives 
(±)-16a-c and (±)-18a/c against varicella-zoster virus (TK+VZV, thymidine kinase positive strain, 
and TK−VZV, thymidine kinase deficient strain) in human embryonic lung (HEL) cells. Even 
when, strictly speaking, no specific antiviral effects were noted, if the data for the TK+VZV 
(OKA strain) are analysed in more detail, derivative 18a can be interpreted as specifically 





General Procedures. All chemicals used were of reagent grade, obtained from Aldrich 
Chemical Co. and used without further purification. Starting materials 13a/b were prepared 
following previously reported methods.8,15 Melting points were measured in a Reichert Kofler 
Thermopan and are uncorrected. Infrared spectra were recorded in a Perkin-Elmer 1640 FTIR 
spectrophotometer. 1H and 13C NMR spectra were recorded in a Bruker AMX 300 spectrometer 
at 300 and 75.47 MHz, respectively, using TMS as internal standard (chemical shifts in δ values, 
J in Hz). Mass spectra were recorded on a Micromass Autoespec (EI and HRMS) and on a 
Bruker Microtof (ESI-TOF) spectrometers. Microanalyses were performed in a Perkin-Elmer 
240B Elemental Analyser at the University of Santiago Microanalysis Service. Analyses 
indicated by the symbols of elements were within ±0.4% of the theoretical values. Flash 
chromatography was performed on silica gel (Merck 60, 230–240 mesh) and analytical TLC on 
pre-coated silica gel plates (Merck 60 F254, 0.25 mm). 
 
X-Ray crystal structure determination. Single crystals of (±)-16a suitable for X-ray 
diffractometry were obtained by dissolving crystals of the already purified material in the 
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minimum quantity of cold THF in an open vial that was then placed in a larger container with a 
little hexane in its bottom; the container was closed, and after a few days in a cool, dark place 
free from vibrations afforded the desired single crystals. This were mounted in an inert oil and 
transferred to the cold gas stream of the diffractometer. Empirical formula: C30H35N3O2Si; 
formula weight: 497.70; 0.45 × 0.23 × 0.10 mm3; crystal colour: colourless; habit: prismatic; 
crystal system: triclinic; lattice type: plate; lattice parameters: a = 7.4396(17) Å, b = 9.728(2) Å, 
c = 20.073(5) Å, α = 89.570(4)°, β = 84.621(4)°, γ = 72.628(4)°, V = 1380.0(5) Å
3
; space group: 
P-1; Z = 2; Dcalc = 1.198 Mg/m3; R1 = 0.0459, wR2 = 0.1109. Diffractometer: Smart-1000 
BRUKER.20 
Epoxidation of tert-butyldimethylsilyl (cyclopent-3-enyl)methyl ether (13a) and tert-
butyldiphenylsilyl (cyclopent-3-enyl)methyl ether (13b). A solution of the corresponding 
alkene 13a15 or 13b8 (1 mmol) in dry CH2Cl2 (5 mL) was slowly added to a well stirred 
suspension of MCPBA (1.2 mmol) in dry CH2Cl2 (5 mL). The reaction mixture was then heated 
at reflux until complete disappearance of the starting material was detected by TLC. The solution 
was then cooled to 0ºC, the solid in suspension filtered and washed with a small amount of cold 
CH2Cl2. The filtrate was washed with a 10% aqueous solution of Na2SO3 (10 mL), a 10% 
aqueous solution of NaHCO3 (10 mL) and brine (10 mL). The organic layer was dried (Na2SO4) 
and the solvent concentrated under reduced pressure. The corresponding residue was purified by 
flash column chromatography (see below for further details). 
cis-tert-Butyldimethylsilyl (3,4-epoxycyclopentyl)methyl ether 14a and trans-tert-
butyldimethylsilyl (3,4-epoxycyclopentyl)methyl ether (14b). A first flash column 
chromatography of the crude reaction product using CH2Cl2 as eluent afforded the pure mixture 
of the epoxides 14a/b in a 91% yield, an increase of a 24% in the previously reported yield.14,15 
A second column chromatography using hexane-CH2Cl2 1:1 as eluent afforded successively 14a 
(9%), 14a+14b (60%) and 14b (31%). The physical data for 14a/b were coincident with those 
reported in the bibliography.15 
cis-tert-Butyldiphenylsilyl (3,4-epoxycyclopentyl)methyl ether (14c) and trans-tert-
butyldiphenylsilyl (3,4-epoxycyclopentyl)methyl ether (14d). The crude reaction mixture was 
chromatographed (silica gel, hexane–EtOAc 30:1 as eluent). The non-void fractions afforded the 
pure mixture of epoxides 14c/d in a 81% yield. Iterative recrystallization (hexane–EtOAc 10:1) 
of 14c or 14d-enriched fractions obtained after the above mentioned chromatography allow us to 
isolate pure samples of the isomers that were used for the physical characterization of the 
compounds. 
14c. Low melting point white solid. IR (KBr) ν: 3068, 3029, 2951, 2928, 2856, 1429, 1376, 
1113, 1016, 997, 841, 828, 790, 744, 704, 688, 616, 506 cm-1. 1H NMR (CDCl3) δ: 7.68-7.65 (m, 
4H); 7.43-7.35 (m, 6H); 3.52 (d, 2H, J = 8.1 Hz, OCH2); 3.46 (virtual s, 2H, 3-H + 4-H); 2.39-
2.28 (m, 1H); 1.93 (dd, 2H, J = 14.9, 1.8 Hz, 5-CHH + 2-CHH); 1.80 (dd, 2H, J = 14.9, 9.1 Hz, 
5-CHH + 2-CHH); 1.07 [s, 9H, C(CH3)3] ppm. MS (EI m/z): 296 [(M+1)-(tert-Bu), 3), 295 [(M)-
(tert-Bu), 13], 265 (17), 247 (17), 217 (13), 200 (18), 199 (100), 197 (13), 187 (15), 183 (17), 
181 (21), 139 (23), 135 (13), 104 (17), 91 (10), 77 (20), 57 (20). 
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14d. Low melting point white solid. IR (KBr) ν: 3047, 2927, 2886, 2855, 1427, 1114, 839, 822, 
742, 701, 609 cm-1.1H NMR (CDCl3) δ: 7.66-7.63 (m, 4H); 7.43-7.35 (m, 6H); 3.60 (d, 2H, J = 
5.0 Hz, OCH2); 3.48 (virtual s, 2H, 3-H + 4-H); 2.15-2.04 (m, 3H); 1.56-1.49 (m, 2H); 1.05 [s, 
9H, C(CH3)3] ppm. 13C NMR/DEPT (CDCl3) δ: 136.0 (CH), 134.2 (C), 130.0 (CH), 128.0 (CH), 
66.1 (CH2), 57.6 (CH), 35.7 (CH), 31.1 (CH2), 27.2 [C(CH3)3], 19.7 [C(CH3)3] ppm. MS (EI 
m/z): 352 (M, 1), 296 (18), 295 (73), 199 (100), 197 (20), 187 (28), 183 (31), 181 (35), 169 (20), 
161 (16), 139 (43), 123 (17), 117 (21), 105 (21), 57 (21). 
Monoprotected azidodiols (±)-15a/b and (±)-15c/d. LiClO4 (25 mmol) and NaN3 (5 mmol) 
were added to a solution of the corresponding mixture of epoxides 14a or 14b (1 mmol) in dry 
CH3CN (10 mL) under Ar atmosphere. The subsequent mixture was stirred at 75ºC for 78 hours. 
Once the reaction was complete, the mixture was cooled to room temperature, diluted with water 
50 mL and extracted with ether (3 x 25 mL). The organic layer was dried (Na2SO4) and the 
solvents evaporated under reduced pressure yielding an oily residue that was purified by flash 
column chromatography (see below for further details). 
(±)-t-2-Azido-c-4-(tert-butyldimethylsilyloxymethyl)cyclopentan-r-1-ol ((±)-15a) and (±)-t-2-
azido-t-4-(tert-butyldimethylsilyloxymethyl)cyclopentan-r-1-ol ((±)-15b). The crude mixture 
of isomers (obtained in 86% yield) was subjected to column chromatography on silica gel using 
hexane–EtOAc 15:1 as eluent to give, successively, (±)-15a (24%) in a first group of fractions 
and a mixture of (±)-15a/b (10%) in a second group. A third group of fractions, eluted with 
hexane–EtOAc 10:1, afforded (±)-15b (66%).  
(±)-15a. Colourless oil. IR (film) ν: 3423, 2931, 2857, 2103, 1466, 1255, 1093, 1033, 836, 778 
cm-1. 1H NMR (CDCl3) δ: 3.94-3.92 (m, 1H, 1-H); 3.83-3.81 (m, 1H, 2-H); 3.62-3.54 (m, 3H); 
2.50-2.39 (m, 1H); 2.26-2.16 (m, 1H); 1.95-1.91 (m, 1H); 1.87-1.83 (m, 1H); 1.54-1.49 (m, 1H); 
0.91 [s, 9H, C(CH3)3]; 0.09 [s, 6H, Si(CH3)2] ppm. 13C NMR/DEPT (CDCl3) δ: 76.3 (CH), 69.5 
(CH), 66.0 (CH2), 37.2 (CH), 35.8 (CH2), 30.6 (CH2), 26.3 [C(CH3)3], 18.8 [C(CH3)3], -5.1 
[Si(CH3)2], -5.2 [Si(CH3)2] ppm. MS (EI m/z): 272 (M +1, 1), 214 (38), 186 (49), 171 (63), 168 
(49), 157 (27), 156 (22), 143 (38), 142 (38), 141 (26), 138 (20), 130 (30), 129 (24), 128 (35), 118 
(26), 115 (70), 112 (43), 105 (30), 100 (37), 99 (30), 97 (63), 94 (90), 90 (59), 85 (30), 79 (35), 
77 (32), 73 (100). HRMS m/z calcd for C12H25N3O2Si, 271.1716; found, 271.1735. 
(±)-15b. Colourless oil. IR (film) ν: 3383, 2929, 2857, 2104, 1472, 1256, 1090, 1005, 837, 776 
cm-1. 1H NMR (CDCl3) δ: 4.10-4.03 (m, 1H, 1-H); 3.70-3.63 (m, 1H, 2-H); 3.49 (d, 2H, J = 6.0 
Hz, OCH2); 2.38-2.29 (m, 1H, 4-H); 2.21-2.06 (m, 1H); 1.86-1.62 (m, 3H); 1.50-1.40 (m, 1H); 
0.89 [s, 9H, C(CH3)3]; 0.04 [s, 6H, Si(CH3)2].ppm 13C NMR/DEPT (CDCl3) δ: 77.9 (CH), 68.8 
(CH), 66.8 (CH2), 37.0 (CH), 35.2 (CH2), 31.9 (CH2), 26.3 [C(CH3)3], 18.7 [C(CH3)3], -5.0 
[Si(CH3)2] ppm. Most of this physical data are coincident with the previously reported.15 MS (EI 
m/z): 214 [M-(tert-Bu), 1], 166 (8), 115 (10), 105 (50), 99 (8), 94 (38), 93 (11), 89 (11), 80 (25), 
77 (13), 76 (10), 75 (100), 73 (28), 67 (47). HRMS m/z calcd for C12H25N3O2Si, 271.1716; 
found, 271.1738. 
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(±)-t-2-Azido-c-4-(tert-butyldiphenylsilyloxymethyl)cyclopentan-r-1-ol ((±)-15c) and (±)-t-2-
azido-t-4-(tert-butyldiphenylsilyloxymethyl)cyclopentan-r-1-ol ((±)-15d). Partial resolution of 
the crude mixture of isomers (obtained in 94% yield) was achieved by column chromatography 
on silica gel using CH2Cl2 as eluent to give, successively, (±)-15d (58%) in the first group of 
fractions, a mixture of (±)-15c/d (17%) in the second group and (±)-15c (25%) in the last group 
of fractions.  
(±)-15c. Colourless oil. IR (film) ν: 3404, 2934, 2879, 2859, 2102, 1428, 1255, 1110, 1029, 821, 
741, 702, 611 cm-1. 1H NMR (CDCl3) δ: 7.69-7.66 (m, 4H); 7.45-7.37 (m, 6H); 4.09 (dd, 1H, J = 
12.6, 6.0 Hz, 1-H); 3.70 (dd, 1H, J = 13.7, 7.5 Hz, 2-H); 3.57 (d, 2H, J = 5.9 Hz, PhCH2); 2.46-
2.36 (m, 1H); 2.21 (dd, 1H, J = 13.3, 7.5 Hz); 2.08 (virtual s, 1H, D2O exchangeable, OH); 1.87 
(q, 1 H, J = 6.9 Hz); 1.76-1.67 (m, 1H); 1.52 (dt, 1H, J = 13.3, 8.3 Hz); 1.08 [s, 9H, C(CH3)3] 
ppm.13C NMR/ DEPT (CDCl3) δ: 136.0 (CH), 134.1 (C), 134.1 (C), 130.1 (CH), 128.1 (CH), 
77.3 (CH), 68.9 (CH), 67.5 (CH2), 37.1 (CH), 35.2 (CH2), 32.1 (CH2), 27.3 [C(CH3)3], 19.7 
[C(CH3)3] ppm. MS (EI m/z): 338 [M-(tert-Bu), 14], 232 (31), 200 (18), 199 (100), 197 (17), 183 
(21), 181 (26), 176 (11), 161 (16), 139 (10), 135 (11), 105 (17), 77 (11), 57 (22). HRMS m/z 
calcd for C22H29N3O2Si, 395.2029; found, 395.2011. 
(±)-15d. Colourless oil. IR (film) ν: 3404, 3069, 2934, 2879, 2859, 2102, 1428, 1110, 702 cm-1. 
1H NMR (CDCl3) δ: 7.69-7.66 (m, 4H); 7.46-7.38 (m, 6H); 4.03 (virtual s, 1H, 1-H); 3.84 (q, 
1H, J = 3.2 Hz); 3.61 and 3.56 (AB part, ABM system, 2H, J = 10.0, 4.0 Hz, PhCH2); 3.14-3.12 
(m, 1H, D2O exchangeable, OH); 2.45-2.35 (m, 1H); 2.27-2.17 (m, 1H); 2.11-2.02 (m, 1H); 
1.87-1.78 (m, 1H); 1.59 (dt, 1H, J = 13.8, 4.3 Hz); 1.09 [s, 9H, C(CH3)3] ppm. 13C NMR/DEPT 
(CDCl3) δ: 136.1 (CH), 136.0 (CH), 133.3 (C), 133.2 (C), 130.3 (CH), 130.3 (CH), 128.2 (CH), 
76.8 (CH), 69.1 (CH), 67.1 (CH2), 37.1 (CH), 35.8 (CH2), 31.0 (CH2), 27.3 [C(CH3)3], 19.6 
[C(CH3)3] ppm. MS (EI m/z): 338 [M-(tert-Bu), 3], 201 (5), 200 (18), 199 (100), 197 (8), 183 
(7), 181 (12), 161 (6), 139 (12), 135 (9), 105 (10), 94 (21), 77 (12), 67 (26), 58 (10), 57 (7). 
HRMS m/z calcd for C22H29N3O2Si, 395.2029; found, 395.2047. 
(±)-t-4-(tert-Butyldiphenylsilyloxymethyl)-t-2-(4-aryl-1H-1,2,3-triazol-1-yl-r-1-
cyclopentanols (±)-16a-c and (±)-c-4-(tert-butyldiphenylsilyloxymethyl)-t-2-(4-aryl-1H-
1,2,3-triazol-1-yl-r-1-cyclopentanols (±)-17a-c.  
Method A. A suspension of the corresponding monoprotected azidodiol (±)-15c/d (1 mmol), 
aryl alkyne (2 mmol), a catalytic amount of CuI (0.05–0.1 mmol) and DIPEA (2 mmol) in dry 
THF (50 mL) was stirred under the conditions specified in Table 1.The reactions were monitored 
by TLC until the complete disappearance of the starting material. The yellow solid in suspension 
was then filtered, the solvents were removed under reduced pressure, and resulting residue was 
dissolved in EtOAc and washed with water. The organic layer was dried (Na2SO4) and the 
solvent removed under reduced pressure. The obtained residue was purified by column 
chromatography on silica gel (see below for further details). 
Method B. A suspension of the corresponding monoprotected azidodiol (±)-15c/d (1 mmol), aryl 
alkyne (2 mmol), CuI (1–2 mmol) and DIPEA (50 mmol) in dry THF (50 mL) was stirred under 
ISSN 1551-7012 Page 161 ©ARKAT USA, Inc. 
Issue in Honor of Prof. Benito Alcaide ARKIVOC 2010 (iii) 152-168 
the conditions specified in Table 1. The reactions were monitored by TLC and the work-up 
carried out in the same manner as for Method A. 
(±)-c-4-(tert-Butyldiphenylsilyloxymethyl)-t-2-(4-phenyl-1H-1,2,3-triazol-1-yl)-r-1-
cyclopentanol ((±)-16a) and (±)-c-4-(tert-butyldiphenylsilyloxymethyl)-t-2-(4-phenyl -5-
iodo-1H-1,2,3-triazol-1-yl)-r-1-cyclopentanol ((±)-18a).  
Method A. The non-void fractions eluted successively with hexane–EtOAc 7:1 and 4:1 afforded 
successively (±)-18a (13%) and (±)-16a (30%).  
Method B. The non-void fractions eluting with hexane–EtOAc 7:1 and 4:1 afforded (±)-18a 
(3%) and (±)-16a (72%) as a white solid that presented identical spectroscopic features to that 
using Method A.  
(±)-16a. White solid, m.p. = 102-103 ºC (recrystallised from THF-hexane). IR (KBr) ν: 3279, 
3138, 3069, 2857, 1424, 1109, 1075, 699 cm-1. 1H NMR (CDCl3) δ: 7.80 (dd, 2H, J = 6.9, 1.5 
Hz, 2H); 7.72 (s, 1H, 5-Htriazole); 7.69 (dd, 4H, J = 6.5, 1.2 Hz, 4H); 7.49-7.35 (m, 9H); 4.68-4.63 
(m, 1H, 1-H); 4.51 (q, 1H, J = 6.1 Hz, 2-H); 3.67 (d, 2H, J = 4.6 Hz, CH2O); 3.63 (d, 1H, J = 5.7 
Hz, D2O exchangeable, OH); 2.63-2.59 (m, 1H); 2.34 (virtual, 2H, J = 2.2 Hz, 3-H2); 2.23-2.20 
(m, 1H); 1.79-1.71 (m, 1H); 1.10 [s, 9H, C(CH3)3] ppm.13C NMR/DEPT (CDCl3) δ: 147.4 (C), 
135.6 (CH), 133.1 (C), 130.5 (C), 129.9 (CH), 128.8 (CH), 128.1 (CH), 127.8 (C), 125.6 (CH), 
119.3 (CH), 77.5 (CH), 67.8 (CH), 66.8 (CH2), 36.4 (CH), 34.9 (CH2), 31.2 (CH2), 26.9 
[C(CH3)], 19.3 (C) ppm. MS (ESI-TOF m/z %): 498.25 (M+1, 100). Anal. Calcd for 
C30H35N3O2Si (497.70): C, 72.40; H, 7.09; N, 8.44. Found: C, 72.76; H, 7.32; N, 8.51. 
(±)-18a. White solid, m.p. = 188-190 ºC (recrystallised from EtOAc-hexane). IR (KBr) ν: 3391, 
2929, 2855, 1425, 1327, 1107, 1006, 798, 699 cm-1. 1H NMR (CDCl3) δ: 7.91-7.89 (m, 2H); 
7.69-7.66 (m, 4H); 7.46-7.23 (m, 9H); 4.84-4.81 (m, 1H); 4.66-4.63 (m, 1H); 3.67 (d, 2H, J = 3.9 
Hz, CH2O); 3.36 (d, 1H, J = 7.2 Hz, D2O exchangeable, OH); 2.77-2.69 (m, 1H); 2.45-2.31 (m, 
3H); 1,75 (dt, 1H, J = 13.7, 5.7 Hz, 5-HH); 1.10 [s, 9H, C(CH3)3] ppm. 13C NMR/DEPT (CDCl3) 
δ: 135.6 (CH), 132.8 (C), 129.9 (CH), 128.5 (CH), 127.8 (CH), 127.5 (CH), 76.8 (CH), 69.0 
(CH), 66.7 (CH2), 37.1 (CH), 35.1 (CH2), 31.7 (CH2), 26.9 [C(CH3)], 19.2 (C) ppm. Anal. Calcd 
for C30H34IN3O2Si (623.60): C, 57.78; H, 5.50; N, 6.74. Found: C, 58.07; H, 5.35; N, 6.99. 
(±)-c-4-(tert-Butyldiphenylsilyloxymethyl)-t-2-[4-(4-methylphenyl)-1H-1,2,3-triazol-1-yl]-r-
1-cyclopentanol ((±)-16b) and (±)-c-4-(tert-butyldiphenylsilyloxymethyl)-t-2-[4-(4-4-
methylphenyl)-5-iodo-1H-1,2,3-triazol-1-yl]-r-1-cyclopentanol ((±)-18b).  
Method A. The non-void fractions eluted with hexane–EtOAc 5:1 afforded successively 
unaltered (±)-15c (42%), (±)-18b (4%) and (±)-16b (42%).  
(±)-16a. hite solid, m.p. = 126-127 ºC. IR (KBr) ν: 3236, 2930, 2856, 1464, 1428, 1112, 1081, 
802, 701 cm-1. 1H NMR (CDCl3) δ: 7.69-7.63 (m, 6H); 7.64 (s, 1H, 5-Htriazole); 7.45-7.36 (m, 
6H); 7.20-7.19 (m, 2H); 4.65-4.60 (m, 1H, 2-H); 4.50-4.47 (m, 1H, 1-H); 3.65-3.61 (m, 3H, 
simplified to a duplet once treated with D2O, J = 4.0 Hz, OCH2 + OH); 2.59-2.56 (m, 1H); 2.36 
(s, 3H, CH3); 2.34-2.26 (m, 3H); 1.70 (dt, 1H, J = 13.4, 7.0 Hz, 5-HH); 1.07 [9H, s, C(CH3)3] 
ppm. 13C NMR/DEPT (CDCl3) δ: 147.5 (C), 138.0 (C), 135.6 (CH), 135.6 (CH), 133.1 (C), 
133.1 (C), 129.9 (CH), 129.5 (CH), 127.8 (CH), 127.6 (C), 125.5 (CH), 118.9 (CH), 77.4 (CH), 
ISSN 1551-7012 Page 162 ©ARKAT USA, Inc. 
Issue in Honor of Prof. Benito Alcaide ARKIVOC 2010 (iii) 152-168 
67.7 (CH), 66.8 (CH2), 36.4 (CH), 34.9 (CH2), 31.2 (CH2), 26.9 [C(CH3)], 21.3 (CH3), 19.3 (C) 
ppm. MS (EI m/z): 455 (16), 454 (45), 295 (47), 265 (34), 217 (30), 200 (19), 199 (100), 160 
(21), 139 (18), 135 (22), 130 (25). Anal. Calcd for C31H37N3O2Si (511.26): C, 72.76; H, 7.29; N, 
8.21. Found: C, 73.11; H, 7.44; N, 8.38.  
(±)-18b. White solid, m.p. = 153-154 ºC. IR (KBr) ν: 3323, 2927, 2855, 1109, 819, 701 cm-1.1H 
NMR (CDCl3) δ: 7.80-7.77 (m, 2H); 7.69-7.66 (m, 4H); 7.46-7.37 (m, 6H); 7.23-7.22 (m, 2H); 
4.81 (dt, 1H, J = 7.8, 4.7 Hz, 2-H); 4.65-4.62 (m, 1H, 1-H); 3.65 (d, 2H, J = 4.1 Hz, OCH2); 
2.74-2.71 (m, 1H); 2.45-2.40 (m, 1H); 2.38 (s, 3H, CH3); 2.37-2.31 (m, 3H, one of them D2O 
exchangeable, OH); 1.75 (dt, 1H, J = 13.8, 5.8 Hz, 5-HH); 1.09 [s, 9H, C(CH3)3] ppm. 13C 
NMR/DEPT (CDCl3) δ: 149.7 (C), 138.4 (C), 135.7 (CH), 132.9 (C), 129.9 (CH), 129.2 (CH), 
127.8 (CH), 127.5 (CH), 76.7 (CH), 69.0 (CH), 66.7 (CH2), 37.1 (CH), 35.1 (CH2), 31.9 (CH2), 
26.9 [C(CH3)], 21.3 (CH3), 19.3 (C) ppm. MS (EI m/z): 580 (15), 208 (19), 199 (100), 181 (21), 
139 (21), 135 (40), 129 (19). Anal. Calcd for C30H34IN3O2Si (497.70): C, 57.78; H, 5.50; N, 
6.74. Found: C, 58.11; H, 5.82; N, 6.63. 
(±)-c-4-(tert-Butyldiphenylsilyloxymethyl)-t-2-[4-(4-methoxyphenyl)-1H-1,2,3-tria zol-1-yl]-
r-1-cyclopentanol ((±)-16c) and (±)-c-4-(terc-butyldiphenyl-silyloxymethyl)-t-2-[4-(4-
methoxyphenyl)-5-iodo-1H-1,2,3-triazol-1-yl]-r-1-cyclopentanol ((±)-18c).  
Method A. The non-void fractions eluted with hexane–EtOAc 5:1 afforded successively 
unaltered (±)-15c (42%) and (±)-18c (11%). A second group of fractions eluted using hexane–
EtOAc 3:1 afforded , after evaporation under reduced pressure of the solvents, (±)-16c (23%). 
(±)-16c. Yellowish oil. IR (film) ν: 2925, 2856, 1616, 1460, 1376, 1255, 1106, 703 cm-1.1H 
NMR (CDCl3) δ: 7.70-7.67 (m, 6H); 7.61 (s, 1H, 5-Htriazole); 7.48-7.36 (m, 6H); 6.93 (virtual d, 
2H, J = 8.5 Hz); 4.67-4.60 (m, 1H, 1-H); 4.52-4.50 (m, 1H); 3.84 (s, 3H, OCH3); 3.81-3.80 (m, 
1H, D2O exchangeable ); 3.66 (d, 2H, J = 4.4 Hz, OCH2); 2.60-2.57 (m, 1H); 2.39-2.27 (m, 3H); 
1.79-1.64 (m, 1H); 1.09 [s, 9H, C(CH3)3] ppm. 13C NMR/DEPT (CDCl3) δ (ppm): 159.5 (C), 
147.0 (C), 135.6 (CH), 133.1 (C), 129.8 (CH), 127.8 (CH), 127.4 (C), 126.9 (CH), 123.1 (C), 
118.6 (CH), 114.2 (CH), 77.4 (CH), 67.8 (CH), 66.9 (CH2), 55.3 (OCH3), 36.1 (CH), 34.8 
C(CH2), 31.3 (CH2), 26,9 [C(CH3)], 19,3 (C) ppm. MS (ESI-TOF m/z %): 528.27 (M+1, 100). 
HRMS: calcd for C31H37N3O3Si, 527.2604; found 527.2622). 
(±)-18c. White solid, m.p. = 167-168 ºC. IR (KBr) ν: 3366, 2929, 2857, 1477, 1245, 1006, 834, 
703 cm-1. 1H NMR (CDCl3) δ: 7.87-7.84 (d, 2H, J = 8.8 Hz); 7.69-7.66 (m, 4H); 7.46-7.37 (m, 
6H); 7.01 (d, 2H, J = 8.8 Hz); 4.85-4.83 (m, 1H, 2-H); 4.66-4.64 (m, 1H, 1-H); 3.86 (s, 3H, 
OCH3); 3.67 (d, 2H, J = 3.8 Hz, CH2O); 3.42 (d, 1H, D2O exchangeable, J = 7.3 Hz, OH); 2.79-
2.77 (m, 1H); 2.47-2.27 (m, 3H); 1.80-1.76 (m, 1H); 1.11 [s, 9H, C(CH3)3)] ppm. 13C 
NMR/DEPT (CDCl3) δ: 159.8 (C), 149.6 (C), 135.7 (CH), 132.8 (C), 129.9 (CH), 128.9 (CH), 
127.8 (CH), 122.78 (C), 113.9 (CH), 76.8 (CH), 69.0 (CH), 66.7 (CH2), 55.3 (OCH3), 37.1 (CH), 
35.1 (CH2), 31.8 (CH2), 27.0 [C(CH3)3], 19.3 (C) ppm. Anal. Calcd for C31H36IN3O3Si (653.63): 
C, 56.96; H, 5.55; N, 6.43. Found: C, 57.21; H, 5.86; N, 6.57. 
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(±)-t-4-(tert-Butyldiphenylsilyloxymethyl)-t-2-(4-phenyl-1H-1,2,3-triazol-1-yl)-r-1-
cyclopentanol ((±)-17a) and (±)-t-4-(tert-butyldiphenylsilyloxymethyl)-t-2-(4-phenyl-5-iodo-
1H-1,2,3-triazol-1-yl)-r-1-cyclopentanol ((±)-19a).  
Method B. The non-void fractions eluted with hexane–EtOAc 5:1 afforded (±)-19a (5%). A 
second group of fractions eluted using hexane–EtOAc 2:1 afforded, after evaporation of the 
solvents under reduced pressure, (±)-17a (64%). 
(±)-17a. Crystalline white solid, m.p. = 110-112 ºC (chromatographically purified product 
washed with acetone). IR (KBr) ν: 3240, 2859, 1461, 1429, 1383, 1114, 1077, 1004, 771, 700 
cm-1. 1H NMR (CDCl3) δ: 7.79-7.75 (dd, 2H, J = 6.9, 1.4 Hz, 2H); 7.73(s, 1H, 5-Htriazole); 7.67-
7.64 (m, 4H); 7.46-7.31 (m, 9H); 4.64-4.56 (m, 2H); 3.66 (dd, 2H, J = 5.4, 1.5 Hz, OCH2); 3.03 
(s, 1H, D2O exchangeable, OH); 2.56-2.44 (m, 2H); 2.16-2.02 (m, 2H); 1.96-1.89 (m, 1H); 1.10 
[s, 9H, C(CH3)3] ppm. 13C NMR/DEPT (CDCl3) δ: 146.9 (C), 135.5 (CH), 133.5 (C) 130.2 (C), 
129.7 (CH), 128.7 (CH), 128.1 (CH), 127.7 (CH), 125.5 (CH), 119.1 (CH), 76.5 (CH), 68.6 
(CH), 67.0 (CH2), 36.3 (CH), 34.1 (CH2), 32.9 (CH2), 26.9 [C(CH3)], 19.3 (C) ppm. MS (EI 
m/z): 441 (30), 440 (85), 217 (22), 199 (100), 197 (27), 183 (38), 181 (32), 167 (23), 139 (29), 
116 (25), 105 (28), 77 (38), 58 (41). Anal. Calcd for C30H35N3O2Si (497.25): C, 72.40; H, 7.09; 
N, 8.44. Found: C, 72.67; H, 7.32; N, 8.69. 
(±)-19a. Colourless oil. IR (film) ν: 3365, 2928, 2857, 1109, 771 cm-1. 1H NMR (CDCl3) δ: 7.91-
7.87 (m, 2H); 7.68-7.66 (m, 4H); 7.49-7.35 (m, 9H); 5.01 (q, 2H, J = 7.2 Hz, 2-H); 4.71 (dt, 1H, 
J = 10.3, 7.2 Hz, 1-H); 3.66 (d, 2H, J = 5.7 Hz, OCH2); 2.59-2.45 (m, 2H); 2.20-2.11 (m, 1H); 
2.03-1.87 (m, 2H); 1.06 [s, 9H, C(CH3)3] ppm. 13C NMR/DEPT (CDCl3) δ: 135.6 (CH), 133.6 
(C), 130.2 (C), 129.7 (CH), 128.6 (CH), 128.5 (C), 127.7 (CH), 127.6 (C), 75.8 (CH), 68.8 (CH), 
67.0 (CH2), 36.6 (CH), 34.4 (CH2), 33.6 (CH2), 26.9 [C(CH3)], 19.3 (C) ppm. MS (EI m/z): 567 
[M – (tert-Bu), 19], 566 (57), 217 (26), 199 (100), 197 (29), 183 (32), 181 (30), 139 (26), 135 
(57), 116, (29), 115 (25), 105 (25), 89 (26), 77 (26). HRMS m/z calcd for C30H34N3O2Si, 
623.1465; found, 623.1484. 
(±)-t-4-(tert-Butyldiphenylsilyloxymethyl)-t-2-[4-(4-methylphenyl)-1H-1,2,3-triazol-1-yl]-r-
1-cyclopentanol ((±)-17b) and (±)-t-4-(tert-butyldiphenylsilyloxymethyl)-t-2-[4-(4-
methylphenyl)-5-iodo-1H-1,2,3-triazol-1-yl]-r-1-cyclopentanol ((±)-19b).  
Method B. the non-void fractions eluted with hexane–EtOAc 3:1 afforded successively 
unaltered (±)-19b (5%) and (±)-17b (82%). 
(±)-17b: Colourless oil. IR (film) ν: 3352, 3069, 2933, 1463, 1387, 1226, 1109, 1004, 910, 819, 
702 cm-1. 1H NMR (CDCl3) δ: 7.65 (dd, 4H, J = 0.8, 7.9 Hz, 4H); 7.62 (s, 1H, 5-Htriazole); 7.58 (d, 
2H, J = 8.0 Hz); 7.45-7.35 (m, 6H); 7.19 (d, 2H, J = 8.0 Hz, 2-H); 4.62-4.56 (2H, m); 3.65 (dd, 
2H, J = 5.6, 2.3 Hz, O CH2); 2.52-2.39 (m, 2H); 2.37 (s, 1H, D2O exchangeable, OH); 2.37 (s, 
3H, CH3); 2.15-2.05 (m, 2H); 2.00-1.92 (m,1H); 1.07 [s, 9H, C(CH3)3] ppm. 13C NMR/DEPT 
(CDCl3) δ: 147.2 (C), 137.9 (C), 135.5 (CH), 133.5 (C), 129.8 (CH), 129.4 (CH), 127.7 (CH), 
127.4 (C), 125.5 (CH), 118.6 (CH), 76.4 (CH), 68.4 (CH), 67.0 (CH2), 36.3 (CH), 34.1 (CH2), 
32.8 (CH2), 26.9 [C(CH3)], 21.2 (CH3), 19.3 (C) ppm. MS (EI m/z): 455 (36), 454 (100), 199 
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(39), 197 (12), 183 (16), 181 (15), 135 (18), 115 (15). HRMS m/z calcd for C31H37N3O2Si, 
511.2655; found, 511.2639. 
(±)-19b: Yellowish oil. IR (film) ν: 3330, 2929, 1731, 1428, 1106, 802, 701 cm-1. 1H NMR 
(CDCl3) δ: 7.78-7.68 (virtual d, 2H, J = 8.2 Hz); 7.67-7,62 (m, 4H); 7.43-7.34 (m, 6H); 7.26-
7.22 (m, 2H); 4.97 (q, 1H, J = 7.2 Hz, 2-H); 4.69 (dt, 1H, J = 10.1, 7.2 Hz, 1-H); 3.64 (d, 2H, J = 
5.8 Hz, OCH2); 2.61-2.47 (m, 2H); 2.39 (s, 3H, CH3); 2.15-2.04 (m, 1H); 1.97-1.91 (m, 2H); 
1.04 [s, 9H, C(CH3)3] ppm. 13C NMR/DEPT (CDCl3) δ: 138.5 (C), 135.6 (CH), 133.6 (C), 129.7 
(CH), 129.2 (CH), 127.7 (CH), 127.5 (CH), 127.3 (C), 75.8 (CH), 68.8 (CH), 67.0 (CH2), 36.6 
(CH), 34.4 (CH2), 33.6 (CH2), 26.9 [C(CH3)], 21.3 (CH3), 19.3 (C) ppm. MS (EI m/z): 581 (26), 
580 [(M–tert-Bu), 73], 451 (21), 217 (21), 208 (21), 199 (100), 197 (37), 183 (36), 181 (40), 139 
(21), 135 (72), 130 (29), 129 (21), 105 (27), 103 (23), 97 (23), 77 (26). HRMS m/z calcd for 
C31H36IN3O2Si, 637.1621; found, 637.1647. 
(±)-t-4-(terc-butyldiphenylsilyloxymethyl)-t-2-[4-(4-methoxyphenyl)-1H-1,2,3-tri-azol-1-yl]-
r-1-cyclopentanol ((±)-17c).  
Method B. The non-void fractions eluted with hexane–EtOAc 1:1 afforded (±)-17c (68%). 
(±)-17c. White solid, m.p. = 107-108 ºC. IR (KBr) ν: 3054, 2932, 2857, 1497, 1465, 1429, 1109, 
1078, 1027, 705 cm-1.1H NMR (CDCl3) δ: 7.68-7.65 (m, 4H); 7.60 (s, 1H, 5-Htriazole); 7.56-7.55 
(m, 2H); 7.45-7.35 (m, 6H); 6.90 (virtual d, 2H, J = 8.7 Hz, 2-H); 4.63-4.57 (m, 2H); 3.83 (s, 3H, 
OCH3); 3.70-3.61 (m, 2H); 2.55-2.37 (m, 2H); 2.16-2.05 (m, 2H); 2.04-1.86 (m,1H); 1.07 [s, 9H, 
C(CH3)3] ppm. 13C NMR/DEPT (CDCl3) δ: 159.5 (C), 146.9 (C), 135.5 (CH), 133.5 (C), 129.7 
(CH), 127.7 (CH), 126.8 (CH), 123.0 (C), 118.2 (CH), 114.1 (CH), 76.4 (CH), 68.4 (CH), 67.0 
(CH2), 55.2 (OCH3), 36.2 (CH), 34.1 (CH2), 32.8 (CH2), 26.8 [C(CH3)], 19.2 (C) ppm. MS (EI 
m/z): 471 (36), 470 [(M–tert-Bu), 100], 199 (72), 197 (30), 183 (29), 181 (21), 175 (24), 135 
(38), 121 (22), 117 (20). Anal. Calcd for C31H37N3O3Si (527.26): C, 70.55; H, 7.07; N, 7.96. 
Found: C, 70.77; H, 7.21; N, 8.09. 
Deprotection of terc-butyldiphenylsilyloxymethyl ethers: synthesis of (±)-t-4-
(hydroxymethyl)-t-2-(4-aryl-1H-1,2,3-triazol-1-yl)-r-1-cyclo-pentanols (±)-10a-c and (±)-c-
4-(hydroxymethyl)-t-2-(4-phenyl-1H-1,2,3-triazol-1-yl)-r-1-cyclopentanols (±)-11a-c. A 
solution of the corresponding triazole derivative (±)-16a-c/(±)-17a-c (1 mmol) and TBAF (1M in 
THF, 2mmol) in dry THF (15 mL), was stirred at room temperature under Ar atmosphere until 
complete disappearance of the starting material was detected by TLC. The solvents were then 
evaporated to dryness under reduced pressure, the residue dissolved in EtOAc (15 mL) and 
washed with brine (10 mL). The organic layer was dried (Na2SO4), evaporated under reduced 
pressure and the corresponding crude reaction product purified by flash column chromatography 
using successively EtOAc and acetone as eluents. 
(±)-t-4-(Hydroxymethyl)-t-2-(4-phenyl-1H-1,2,3-triazol-1-yl)-r-1-cyclopentanol ((±)-10a). 
97% Yield, white solid, m.p. = 58-59 ºC. IR (film) ν: 3364, 2924, 1650, 1518, 1047 cm-1. 1H 
NMR (CDCl3) δ: 7.79-7.77 (m, 2H, 2H); 7.76 (s, 1H, 5-Htriazole); 7.44-7.32 (m, 2H); 7.31-7.25 
(m, 1H); 4.74-4.69 (m, 1H, 2-H); 4.49 (virtual q, 1H, J = 5.8 Hz, 1-H); 3.76-3.67 (m, 3H, one of 
them D2O exchangeable, HOCH2 + OH); 2.67-2.62 (m, 1H); 2.45-2.31 (m, 4H); 1.67 (dt, 1H, J = 
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13.7, 5.9 Hz, 3-HH) ppm. 13C NMR/DEPT (CDCl3) δ: 147.5 (C), 130.4 (C), 128.9 (CH), 128.2 
(CH), 125.6 (CH), 119.3 (CH), 77.5 (CH), 68.2 (CH), 65.6 (CH2), 36.7 (CH), 35.2 (CH2), 31.5 
(CH2) ppm. MS (EI m/z): 259 (M, 1), 145 (23), 117 (87), 116 (38), 102 (58), 97 (37), 91 (25), 89 
(28), 83 (32), 81 (28), 79 (31), 77 (25), 71 (41), 69 (63), 67 (42), 58 (100), 57 (75), 55 (74). 
Anal. Calcd for C14H17N3O2 (259.13): C, 64.85; H, 6.61; N, 16.20. Found: C, 65.12; H, 6.93; N, 
16.46. 
(±)-t-4-(Hydroxymethyl)-t-2-(4-(4-methyphenyl)-1H-1,2,3-triazol-1-yl)-r-1-cyclopen tanol 
((±)-10b). 87% Yield, white solid, m.p. = 128-129 ºC. IR (KBr) ν: 3284, 2920, 1454, 1382, 
1053, 816 cm-1. 1H NMR (CDCl3) δ: 7.77 (s, 1H, 5-Htriazole); 7.67 (d, 2H, J = 8.0 Hz); 7.20 (d, 
2H, J = 8.0 Hz); 4.63 (dt, 1H, J = 7.0, 2.9 Hz, 2-H); 4.56 (virtual q, 1H, J = 7.0 Hz, 1-H); 3.71-
3.63 (m, 2H, HOCH2); 2.74 (b s, 2H, D2O exchangeable, 2 OH); 2.59-2.50 (m, 2H); 2.36 (s, 3H, 
CH3); 2.15-2.01 (m, 2H); 1.99-1.89 (m, 1H) ppm. 13C NMR/DEPT (CDCl3) δ: 147.6 (C), 138.0 
(C), 129.5 (CH), 127.7 (C), 125.6 (CH), 118.9 (CH), 76.9 (CH), 67.9 (CH), 66.1 (CH2), 36.4 
(CH), 32.4 (CH2), 29.7 (CH2), 21.3 (CH3) ppm. MS (EI m/z): 273 (M, 19), 158 (19), 131 (100), 
130 (35), 116 (58), 115 (78), 103 (21), 77 (21). Anal. Calcd for C15H19N3O2 (273.33): C, 66.91; 
H, 7.01; N, 15.37. Found: C, 67.22; H, 6.98; N, 15.63. 
(±)-t-4-(Hydroxymethyl)-t-2-(4-(4-methoxyphenyl)-1H-1,2,3-triazol-1-yl)-r-1-cyclo pentanol 
((±)-10c). 99% Yield, white solid, m.p. = 115-116 ºC. IR (KBr) ν: 3350, 3110, 2941, 2885, 1615, 
1495, 1444, 1381, 1251, 1051, 1021 cm-1.1H NMR (acetone-d6) δ: 8.28 (s, 1H, 5-Htriazol); 7.80 (d, 
2H, J = 8.8 Hz); 70 (d, 2H, J = 8.8 Hz); 4.78-4.70 (m, 1H, 2-H); 4.50-4.47 (m, 1H, 1-H); 3.82 (s, 
3H, OCH3); 3.60-3.57 (m, 2H, HOCH2); 2.79-2.93 (m, 2H, D2O exchangeable, 2 OH); 2.52-2.42 
(m, 2H); 2.08-2.01 (m, 2H); 2.00-1.80 (m, 1H) ppm. 13C NMR/DEPT (acetone-d6) δ: 160.7 (C), 
147.9 (C), 127.8 (CH), 125.4 (C), 119.9 (CH), 115.3 (CH), 77.7 (CH), 69.7 (CH), 66.7 (CH2), 
55.9 (OCH3), 382 (CH), 36.5 (CH2), 34.5 (CH2) ppm. MS (EI m/z): 289 (M, 26), 230 (13), 176 
(16), 175 (74), 174 (15), 147 (31), 146 (15), 135 (27), 132 (100), 121 (12), 117 (23), 89 (24), 77 
(11). Anal. Calcd for C15H19N3O3 (289.33): C, 62.27; H, 6.62; N, 14.52. Found: C, 62.59; H, 
6.89; N, 14.36.  
(±)-c-4-(Hydroxymethyl)-t-2-(4-phenyl-1H-1,2,3-triazol-1-yl)-r-1-cyclopentanol ((±)-11a). 
93% Yield, white solid, m.p. = 61-62 ºC. IR (KBr) ν: 3289, 3083, 2939, 1441, 1107, 1042 cm-1. 
1H NMR (CDCl3) δ: 7.79-7.75 (m, 2H); 7.77 (s, 1H, 5-Htriazol); 7.44-7.39 (m, 2H); 7.35-7.31 (m, 
1H); 4.76-4.69 (m, 1H, 2-H), 4.52-4.46 (virtual q, 1H, J = 5.8 Hz, 1-H); 3.76-3.67 (m, 2H, 
HOCH2); 2.68-2.59 (m, 1H); 2.45-2.31 (m, 4H, OH); 1.67 (dt, 1H, J = 13.8, 5.9 Hz, 3-CHH) 
ppm. 13C NMR/DEPT (CDCl3) δ: 147.44 (C), 130.33 (C), 128.85 (CH), 128.22 (CH), 125.64 
(CH), 119.35 (CH), 77.52 (CH), 68.25 (CH), 65.62 (CH2), 36.68 (CH), 35.26 (CH2), 31.56 (CH2) 
ppm. MS (EI m/z): 259 (M, 23), 145 (56), 144 (30), 117 (90), 104 (22), 103 (27), 102 (100), 90 
(28), 89 (38), 79 (22), 69 (24), 67 (39), 58 (44), 55 (24). Anal. Calcd for C14H17N3O2 (259.13): 
C, 64.85; H, 6.61; N, 16.20. Found: C, 64.56; H, 6.78; N, 16.15. 
(±)-c-4-(Hydroxymethyl)-t-2-(4-(4-methylphenyl)-1H-1,2,3-triazol-1-yl)-r-1-cyclopentanol 
((±)-11b). 99% Yield, white solid, m.p. = 119-120 ºC. IR (KBr) ν: 3282, 1649,1517, 1041, 
819 cm-1. 1H NMR (CDCl3) δ: 7.68 (s, 1H, 5-Htriazol); 7.59-7.24 (m, 2H); 7.16 (d, 2H, J = 7.8 
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Hz); 4.69-4.64 (m, 1H, 2-H); 4.46-4.42 (m, 1H, 1-H); 3.67-3.60 (m, 2H, HOCH2); 2.60-2.52 (m, 
1H); 2.33 (s, 3H, CH3); 2.38-2.24 (m, 3H); 1.65-1.61 (m, 1H, 3-HH) ppm. 13C NMR/DEPT 
(CDCl3) δ: 147.6 (C), 138.0 (C), 129.5 (CH), 127.8 (CH), 127.6 (CH), 125.6 (CH), 118.9 (CH), 
77.5 (CH), 68.2 (CH), 65.6 (CH2), 36.7 (CH), 35.3 (CH2), 31.5 (CH2), 21.3 (CH3) ppm. MS (EI 
m/z): 273 (M, 23), 158 (24), 131 (80), 130 (44), 119 (20), 118 (20), 117(23), 116 (83), 115 (100), 
103 (25), 91 (20), 79 (21), 77 (28), 69 (25), 67 (32), 57 (25), 55 (27). Anal. Calcd for 
C15H19N3O2 (273.33): C, 66.91; H, 7.01; N, 15.37. Found: C, 67.26; H, 7.33; N, 15.54. 
(±)-c-4-(Hydroxymethyl)-t-2-(4-(4-methoxyphenyl)-1H-1,2,3-triazol-1-yl)-r-1-cyclopentanol 
((±)-11c). 74% Yield, white solid, m.p. = 124-125ºC. IR (KBr) ν: 3282, 1649,1517, 1041, 
819 cm-1. H NMR (CDCl3) δ: 7.68 (s, 1H, 5-Htriazol); 7.59-7.24 (m, 2H); 7.16 (d, 2H, J = 7.8 Hz); 
4.69-4.64 (m, 1H, 2-H); 4.46-4.42 (m, 1H, 1-H); 3.67-3.60 (m, 2H, HOCH2); 2.60-2.52 (m, 1H); 
2.33 (s, 3H, CH3); 2.38-2.24 (m, 3H); 1.65-1.61 (m, 1H, 3-HH) ppm. 13C NMR/DEPT (CDCl3) 
δ: 147.6. (C), 138.0 (C), 129.5 (CH), 127.8 (CH), 127.6 (CH), 125.6 (CH), 118.9 (CH), 77.5 
(CH), 68.2 (CH), 656 (CH2), 36.7. (CH), 35.3 (CH2), 31.5 (CH2), 21.3 (CH3) ppm. MS (EI m/z): 
273 (M, 23), 158 (24), 131 (80), 130 (44), 119 (20), 118 (20), 117 (23), 116 (83), 115 (100), 103 
(25), 91 (20), 79 (21), 77 (28), 69 (25), 67 (32), 57 (25), 55 (27). Anal. Calcd for C15H19N3O3 
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